Key Points
- CFO Michael Catelani purchased 5,500 Anixa Biosciences shares at an average price of $2.84, investing $15,620 and increasing his ownership by 12.36% to 50,000 shares.
- Anixa shares opened at $2.93, with a market capitalization of approximately $101.85 million and a 52-week range of $2.32 to $5.46. The company reported quarterly EPS of negative $0.08, in line with analyst expectations.
- Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $8.00; institutional investors own 29.13% of the company.
Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CFO Michael Catelani acquired 5,500 shares of the business's stock in a transaction dated Wednesday, September 30th. The stock was purchased at an average price of $2.84 per share, with a total value of $15,620.00. Following the acquisition, the chief financial officer owned 50,000 shares of the company's stock, valued at approximately $142,000. This trade represents a 12.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Anixa Biosciences Stock Up 2.8%
Shares of ANIX stock opened at $2.93 on Thursday. The stock has a 50-day simple moving average of $3.20 and a 200 day simple moving average of $2.97. The stock has a market capitalization of $101.85 million, a P/E ratio of -9.16 and a beta of 0.51. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). On average, sell-side analysts anticipate that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. HC Wainwright reduced their target price on shares of Anixa Biosciences from $7.00 to $6.00 and set a "buy" rating for the company in a report on Tuesday, September 22nd. Zacks Research downgraded Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Weiss Ratings raised Anixa Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 17th. D. Boral Capital restated a "buy" rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th. Finally, Wall Street Zen raised Anixa Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, June 20th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $8.00.
Check Out Our Latest Report on Anixa Biosciences
Hedge Funds Weigh In On Anixa Biosciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIX. Sanctuary Advisors LLC acquired a new stake in Anixa Biosciences during the 2nd quarter valued at $29,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Anixa Biosciences in the second quarter worth $29,000. Integrated Wealth Concepts LLC purchased a new position in shares of Anixa Biosciences during the second quarter valued at $30,000. Simplicity Wealth LLC purchased a new position in shares of Anixa Biosciences during the second quarter valued at $34,000. Finally, NewEdge Wealth LLC purchased a new position in shares of Anixa Biosciences during the second quarter valued at $35,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.
Anixa Biosciences Company Profile
(
Get Free Report)
Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company's research programs are designed to use the immune system to prevent or treat serious illnesses.
Anixa's cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.
In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
